Navigation Links
FDA approves HeartMate II mechanical heart pump for heart-failure patients

NEW YORK (April 25, 2008) -- Heart failure patients at NewYork-Presbyterian Hospital/Columbia University Medical Center were among the first to be implanted with the HeartMate II LVAS (Left Ventricular Assist System) -- a miniature mechanical pump that helps weak hearts pump blood -- that has now received approval by the FDA as of April 21 for broad use as bridge to transplantation. As part of clinical trials leading to approval, 22 patients received the new device at NewYork-Presbyterian/Columbia -- more than any other hospital in the New York area.

Clinical research studies at medical centers, including NewYork-Presbyterian/Columbia, showed the HeartMate II to be safe and effective, with improved quality of life and survival compared with historical norms for heart-failure patients. In addition, the device is designed to be quieter and more durable than other FDA approved devices.

One-eighth the size of the original HeartMate LVAS, the HeartMate II provides continuous blood flow through the circulatory system using only one moving part -- a rotary pumping mechanism.

"For patients whose hearts are unable to effectively pump blood due to severe heart failure, this remarkable device can help them have active lives as they await a heart transplant," says Dr. Yoshifumi Naka, principal investigator of the clinical research studies and director of cardiac transplantation at NewYork-Presbyterian Hospital/Columbia University Medical Center and associate professor of surgery at Columbia University College of Physicians and Surgeons.

With around 2,200 donor hearts available annually, there are large numbers of patients with end-stage heart failure placed on heart transplant waiting lists. These patients would be candidates to receive the HeartMate II LVAS as a therapeutic option to sustain them until transplant.

FDA approval was based on one-year follow-up data from the first 194 HeartMate II patients enrolled in the trial. Highlights included:

  • Survival to cardiac transplantation, recovery or ongoing on HeartMate II support was 80 percent at six months and 77 percent at one year.

  • Eighty-four percent of the patients survived to hospital discharge or transplantation.

  • The incidence of major adverse events with comparable definitions -- including infections, strokes and bleeding requiring surgery -- was significantly lower than what was clinically observed in the previous bridge-to-transplantation study of the HeartMate VE LVAS (HeartMate IIs predecessor).

Currently, NewYork-Presbyterian Hospital/Columbia University Medical Center is participating in a clinical trial of HeartMate II as a long-term therapy (also known as destination therapy) that could potentially also serve as a permanent support option for these patients.


Contact: Belinda Mager
New York- Presbyterian Hospital/Columbia University Medical Center

Related medicine news :

1. FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD
2. FDA Approves New Once-a-Month Dose of Actonel for Postmenopausal Osteoporosis
3. FDA approves VYVANSE, first and only once-daily prodrug stimulant to treat ADHD in adults
5. House Overwhelmingly Approves Renewal and Tripling of Successful U.S. Global AIDS Prevention Effort
6. VeriPrime Approves New Best Practices for Beef Production
7. U.S. EPA Approves Registration of Antimicrobial Copper Alloys
8. Arizona Senate Approves Smoking Cessation Treatments for State Medicaid Beneficiaries
9. CMS Approves Home Sleep Testing for Diagnosis of OSA; AASM Experts Available for Comment
10. FDA Approves Abbotts FreeStyle Navigator(R) Continuous Glucose Monitoring System
11. FDA Approves Aloxi(R) (Palonosetron HCL) Injection for Prevention of Postoperative Nausea and Vomiting
Post Your Comments:
(Date:11/29/2015)... ... ... featured X-wing as part of its monthly Tech Report, which features the latest and ... for NewsWatch, conducted the review and shared with viewers how Woody Guthrie’s Endless Skyway ... are about to become a reality. Where’s the idea from? With inspiration from Star ...
(Date:11/29/2015)... ... November 29, 2015 , ... While conventional walkers afford considerable help ... access to exercise weights. Fortunately, an inventor from Uniontown, Pa., has found a way ... enhance the benefits of a standard walker to improve the user’s quality of life. ...
(Date:11/29/2015)... , ... November 29, 2015 , ... ... and unique analog distortion effect tool designed specially for Final Cut Pro X. ... create limiltess looks with the easy-to-use modification controls. Destoying and creating chaotic distortion ...
(Date:11/29/2015)... ... November 29, 2015 , ... Key Housing, a top-rated corporate ... their December, 2015, featured apartment community: Epic. In showcasing this featured apartment community in ... tight Bay Area rental market to efficiently find housing suitable to their needs by ...
(Date:11/28/2015)... ... November 28, 2015 , ... Safe storage for contraceptive devices ... inventors, one from Lakewood, New Jersey and the other from Bradley Beach, New Jersey, ... to save the expense of having to replace NuvaRings more often than necessary. As ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for ... combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for advanced ... combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for advanced ... has found that immunotherapy can be efficiently combined ...
(Date:11/26/2015)... -- 3D bioprinting market is expected to ... report by Grand View Research Inc. Rising prevalence of chronic ... transplantation is expected to boost the market growth, as 3D ... --> 3D bioprinting market is expected to ... report by Grand View Research Inc. Rising prevalence of chronic ...
(Date:11/26/2015)... 2015 ) ... "2016 Future Horizons and Growth Strategies in ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> ) has announced ... Horizons and Growth Strategies in the German ...
Breaking Medicine Technology: